Logo

American Heart Association

  91
  0


Final ID: Su1116

The Supplementary Anti-Obesity Medication Integration into a Longitudinal Weight Loss (SAIL) Program: Early Experience in a Remote Comprehensive Weight Management Solution In Patients with CardioMetabolic Risk

Abstract Body (Do not enter title and authors here): Background: There is substantial imbalance between the prevalence and treatment of overweight/obesity. Team-based remote care programs have shown promise in closing healthcare delivery gaps for several cardiometabolic disorders, but whether this strategy can enhance the uptake of guideline-directed therapy for weight management remains uncertain.
Methods: In this quality improvement program, we developed and deployed a remote, patient navigator and pharmacist-led, pharmacotherapy-oriented weight management intervention (Supplementary Anti-Obesity Integration into a Longitudinal Weight Loss [SAIL] program). SAIL was conducted within the Partnerships for Reducing Overweight and Obesity with Patient-Centered Strategies 2.0 (PROPS 2.0) program, an ongoing 12-month digital health program pairing an online weight management program (RestoreHealth; HealthFleet, Inc.) with personalized support from health coaches. After 6 months, PROPS 2.0 participants who did not experience weight reduction were offered possible enrollment in SAIL. Pharmacists, enabled by a collaborative drug therapy management program, prescribed, titrated, and monitored anti-obesity medications (AOM) with physician (cardiologist) supervision.
Results: Overall, 2,540 invitations for participation in SAIL were sent to the 5,061 patients enrolled in PROPS 2.0, of whom 200 responded. Of the respondents, 98 (49%) were eligible for SAIL, and 75 patients were enrolled. Based randomly by enrollment period, 45 patients participated without a remote physician visit, while 30 had a video telemedicine visit. Among the 75 program participants, 70 (93%) received a prescription for AOM (29/30 with a visit vs. 41/45 without; P=0.64). After a median follow-up of 143 days (IQR 79-193), 61/70 were taking prescribed AOM (26/29 with a visit vs. 35/41 without; P=0.73) (Figure).
Conclusion: This study extends prior experiences leveraging remote, team-based care, emphasizing the potential of this approach to enhance weight management. Given the dramatic cardiometabolic detriments of prolonged exposure to overweight and obesity, innovative approaches are necessary to meet demand. Remote and team-based care are proven methods to improve care and outcomes and may provide a novel model for delivering care for overweight and obesity. Further studies are needed to ascertain the effectiveness of this strategy on weight-related health outcomes.
  • Ostrominski, John  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Blood, Alexander  ( Brigham and Womens Hospital , Brookline , Massachusetts , United States )
  • Tucci, Michela  ( Brigham and Womens Hospital , Brookline , Massachusetts , United States )
  • Zelle, David  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Baer, Heather  ( Brigham and Womens Hospital , Brookline , Massachusetts , United States )
  • Unlu, Ozan  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Mccarthy, Ashley  ( Brigham and Womens Hospital , Brookline , Massachusetts , United States )
  • Gabovitch, Dan  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Apovian, Caroline  ( Brigham and Womens Hospital , Brookline , Massachusetts , United States )
  • Scirica, Benjamin  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    John Ostrominski: DO NOT have relevant financial relationships | Alexander Blood: DO have relevant financial relationships ; Ownership Interest:AIwithCare:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Past (completed) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Advisor:Porter Health:Past (completed) ; Advisor:Knownwell Health:Past (completed) ; Consultant:HelloHeart:Active (exists now) ; Consultant:Withings:Past (completed) ; Consultant:Walgreens Health:Past (completed) ; Consultant:Milestone Therapeutics:Active (exists now) ; Consultant:Corcept Therapeutics:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Medscape:Active (exists now) ; Consultant:Astra Zeneca:Past (completed) ; Consultant:Boehringer Ingelheim:Active (exists now) | Michela Tucci: DO NOT have relevant financial relationships | David Zelle: DO NOT have relevant financial relationships | Heather Baer: DO NOT have relevant financial relationships | Ozan Unlu: DO NOT have relevant financial relationships | Ashley McCarthy: DO NOT have relevant financial relationships | Dan Gabovitch: DO NOT have relevant financial relationships | Caroline Apovian: No Answer | Benjamin Scirica: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Individual Stocks/Stock Options:Health at Scale, Arboretum Lifesciences, and AIwithCare.com:Active (exists now) ; Consultant:Lexeo:Active (exists now) ; Consultant:Hanmi:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstaZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Abbvie:Active (exists now) ; Research Funding (PI or named investigator):Verve Therapeutics:Active (exists now) ; Researcher:Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Milestone Pharmaceutical:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Advancing Excellence: Innovations in Quality Improvement and Implementation Science

Sunday, 11/17/2024 , 11:30AM - 12:30PM

Abstract Poster Session

More abstracts on this topic:
A Pilot Study Of Dopaminergic Enhancement Of Rehabilitation Therapy Early After Stroke

Cramer Steven, Ventoza Cristina, Shklanko Lauren, Stehman Andrea, Soleimani Nina, Kras Genevieve, Young Brittany, Roberts Pamela, Song Min-keun, Chang Tracy, Su Michael, Brinkman Lorie, Gornbein Jeffrey, Le Vu, Holl Christina, Cardoso Ferreira Isabel, Atkinson Megan, Ha Kara, Nguyen Tiffany, Schwarz Anne, Feldman Marc

Acceptability and Gain of Knowledge of Community Educational Tools About Rheumatic Heart Disease Integrated With Screening In Low-Income Settings

Abrams Jessica, Nunes Maria, Diniz Marina, Fraga Lucas, Paula Luiza, Coelho Cecilia, Tacuri Chavez Luz Marina, Lemos Larissa, Correia Julliane, Ribeiro Antonio, Nascimento Bruno, Sable Craig, Spaziani Alison, Zuhlke Liesl, Cardoso Clareci, Vinhal Wanessa, Ribeiro Isabely, Oliveira Kaciane, Amaral Ingred Beatriz

More abstracts from these authors:
Implementation and Evaluation of an Electronic Health Record Rule-Based System to Identify Heart Failure Patients Eligible for Guideline-Directed Medical Therapy

Hassan Shahzad, Collins Emma, Figueroa Christian, Ruggiero Ryan, Fridley Echo, Varugheese Matthew, Gabovitch Dan, Cannon Christopher, Desai Akshay, Blood Alexander, Scirica Benjamin, Subramaniam Samantha, Wagholikar Kavishwar, Kumar Sanjay, Unlu Ozan, Zelle David, Ostrominski John, Nichols Hunter, Mcpartlin Marian, Twinning Megan

Main Results of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF) Program – A Pragmatic Randomized Study

Blood Alexander, Mcpartlin Marian, Wagholikar Kavishwar, Caberwal Harjeet, Cannon Christopher, Desai Akshay, Scirica Benjamin, Unlu Ozan, Hassan Shahzad, Nichols Hunter, Ostrominski John, Subramaniam Samantha, Zelle David, Figueroa Christian, Varugheese Matthew

You have to be authorized to contact abstract author. Please, Login
Not Available